Rebecca Chaplin (PA to Krina Zondervan)
Kelly Barrett (Research Nurse)
Lisa Buck (Research Nurse)
Rebecca Dragovic (Senior Postdoctoral Fellow)
Kurtis Garbutt (Data Scientist and Programme Manager)
Tatjana Gibbons (DPhil Student)
Adriana Invitti (Visiting Senior Postdoctoral Fellow)
Michal Krassowski (DPhil Student)
Wilhelmina Lucinescu (MRes Student)
Magda Mareckova (DPhil Student)
Nilufer Rahmioglu (Senior Postdoctoral Fellow)
Nina Shigesi (DPhil Student)
Fitnat Topbas (DPhil Student)
Outi Uimari (Visiting Clinical Research Fellow)
Yifan Wang (DPhil Student)
Lydia Coxon (Postdoc, Vincent group)
Lysia Demetriou (Postdoc, Vincent group)
Katy Vincent (Senior Pain Fellow)
I came to Oxford on an Erasmus exchange scholarship in 1993, after an MSc in Biomedical Sciences (Cum Laude, 1995), at Leiden University, the Netherlands. I read for a DPhil (NDOG/DPH, St Edmund Hall, 1999) on the epidemiology of chronic pelvic pain, and was subsequently awarded an MRC Training Research Fellowship in Genetic Epidemiology based at the Wellcome Trust Centre for Human Genetics, which included an MSc in Genetic Epidemiology (Erasmus University Rotterdam, Netherlands, 2001) and research periods at the Queensland Institute for Medical Research, Australia and the Dept of Human Genetics, University of Pittsburgh, USA.
In 2007, I was awarded a Wellcome Trust Research Career Development Fellowship and in 2012 became Co-Director of the Endometriosis CaRe centre in Oxford (with Christian Becker). I was appointed as Professor of Reproductive and Genomic Epidemiology in 2015. I am Fellow by Special Election at St Edmund Hall. I was recognised in 2013 as Outstanding Female Scientist (AcademiaNet, Wellcome Trust nomination), in 2019 through an Honorary Skou Professorship at the University of Aarhus, Denmark, and in 2022 through an Honorary Fellowship ad eundem by the Royal College of Obstetricians and Gynaecologists, UK.
Other current roles include: Research Advisory Board member for the European Research Council, advanced grants panel, and for Wellbeing of Women, UK. Board Member (Hon. Secretary), World Endometriosis Society; Board Member (Hon. Secretary), World Endometriosis Research Foundation; Chair, Research Directions Committee, World Endometriosis Society/World Endometriosis Research Foundation; Research Advisory Board, Wellbeing of Women UK; Lead for Genetic Discovery & Translation in the Oxford University-Bayer Healthcare Endometriosis Alliance; Scientific Advisory Board member of the Boston Center for Endometriosis (Harvard Medical School, USA); Section Head Endometriosis, Faculty 1000; Scientific Advisory Board member for AbbVie Inc, Bayer HealthCare, and Roche Diagnostics.
MSc DPhil FRCOG
Head of Department, Professor of Reproductive & Genomic Epidemiology, Co-Director Endometriosis CaRe Centre.
- Fellow, St Edmund Hall
My group works on understanding the pathogenesis of women's health disorders through genomic, molecular, and environmental epidemiological research methods. We are based within the Oxford Endometriosis CaRe Centre, of which I am co-director, and the Wellcome Centre for Human Genetics (WCHG), and collaborate with a large network of research groups (inter)nationally.
We focus in particular on endometriosis - a common, poorly understood chronic inflammatory condition in women of reproductive age, involving the presence of endometrial-like cells in extra-uterine pelvic sites. The condition causes pain and sub-fertility; is estimated to affect 5-10% of women in their reproductive years (176 million women worldwide and 1.5 million in the UK); has limited diagnostic and treatment options; and has a major impact on health-related quality of life of sufferers and their families.
Heritable factors are involved in endometriosis risk. Identifying which DNA variants underlie this heritability will improve our understanding of pathogenesis and inform treatment development. I co-founded the International Endometriosis Genome Consortium (IEGC) in which we are conducting the largest collaborative genome-wide association studies (GWAS) of endometriosis to date (e.g. Nature Genetics 2011& 2012; Nature Communications 2017). The consortium has recently expanded to 16 research centres contributing GWAS data on over 60,000 women with endometriosis.
In addition to continued genetic discovery work, I have led a large global initiative in endometriosis research to develop standardised deep phenotyping tools and sample collection protocols (WERF EPHect); these are implemented so far in 18 endometriosis research centres worldwide. In the Endometriosis CaRe centre we are currently using WERF EPHect-compliant data and samples from women attending our centre to explore what biological pathways implicated genetic variants 'signpost', and how findings can aid discovery of novel treatment targets and biomarkers.
To this end, within the Centre we have established a programme of translational research and have established very strong links with industry partners to allow translation of our research findings, for example through our Bayer AG - Oxford Scientific Alliance in Gynaecological Therapies. This work is made possible through the much appreciated involvement of many women with and without the disease, who contribute information and samples to our studies and through our many collaborations within the WERF EPHect network and beyond.
The Wellcome Trust; The Medical Research Council; National Institutes of Health USA; World Endometriosis Research Foundation; The European Union; and industry partners (Bayer AG, MDNA Life Sciences, Roche Diagnostics, Volition)